Suppr超能文献

肾移植后的非免疫性并发症。

Non-immunological complications following kidney transplantation.

作者信息

Cohen-Bucay Abraham, Gordon Craig E, Francis Jean M

机构信息

Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico.

Nephrology Department, American British Cowdray Medical Center, Mexico City, 05300, Mexico.

出版信息

F1000Res. 2019 Feb 18;8. doi: 10.12688/f1000research.16627.1. eCollection 2019.

Abstract

Kidney transplantation (KT) is the most effective way to decrease the high morbidity and mortality of patients with end-stage renal disease. However, KT does not completely reverse the damage done by years of decreased kidney function and dialysis. Furthermore, new offending agents (in particular, immunosuppression) added in the post-transplant period increase the risk of complications. Cardiovascular (CV) disease, the leading cause of death in KT recipients, warrants pre-transplant screening based on risk factors. Nevertheless, the screening methods currently used have many shortcomings and a perfect screening modality does not exist. Risk factor modification in the pre- and post-transplant periods is of paramount importance to decrease the rate of CV complications post-transplant, either by lifestyle modification (for example, diet, exercise, and smoking cessation) or by pharmacological means (for example, statins, anti-hyperglycemics, and so on). Post-transplantation diabetes mellitus (PTDM) is a major contributor to mortality in this patient population. Although tacrolimus is a major contributor to PTDM development, changes in immunosuppression are limited by the higher risk of rejection with other agents. Immunosuppression has also been implicated in higher risk of malignancy; therefore, proper cancer screening is needed. Cancer immunotherapy is drastically changing the way certain types of cancer are treated in the general population; however, its use post-transplant is limited by the risk of allograft rejection. As expected, higher risk of infections is also encountered in transplant recipients. When caring for KT recipients, special attention is needed in screening methods, preventive measures, and treatment of infection with BK virus and cytomegalovirus. Hepatitis C virus infection is common in transplant candidates and in the deceased donor pool; however, newly developed direct-acting antivirals have been proven safe and effective in the pre- and post-transplant periods. The most important and recent developments on complications following KT are reviewed in this article.

摘要

肾移植(KT)是降低终末期肾病患者高发病率和死亡率的最有效方法。然而,肾移植并不能完全逆转多年肾功能下降和透析所造成的损害。此外,移植后添加的新的致病因素(特别是免疫抑制)会增加并发症的风险。心血管(CV)疾病是肾移植受者的主要死因,需要根据危险因素进行移植前筛查。然而,目前使用的筛查方法存在许多缺点,且不存在完美的筛查方式。移植前后的危险因素修正对于降低移植后心血管并发症的发生率至关重要,可通过生活方式改变(如饮食、运动和戒烟)或药物手段(如他汀类药物、抗高血糖药物等)来实现。移植后糖尿病(PTDM)是该患者群体死亡的主要原因。虽然他克莫司是PTDM发生的主要因素,但由于使用其他药物会增加排斥反应的风险,免疫抑制的改变受到限制。免疫抑制还与较高的恶性肿瘤风险有关;因此,需要进行适当的癌症筛查。癌症免疫疗法正在彻底改变普通人群中某些类型癌症的治疗方式;然而,其在移植后的使用受到同种异体移植排斥风险的限制。正如预期的那样,移植受者也面临较高的感染风险。在护理肾移植受者时,在筛查方法、预防措施以及BK病毒和巨细胞病毒感染的治疗方面需要特别关注。丙型肝炎病毒感染在移植候选者和已故供体库中很常见;然而,新开发的直接作用抗病毒药物已被证明在移植前后均安全有效。本文综述了肾移植后并发症的最重要和最新进展。

相似文献

1
Non-immunological complications following kidney transplantation.
F1000Res. 2019 Feb 18;8. doi: 10.12688/f1000research.16627.1. eCollection 2019.
2
Hepatitis C virus infection in end-stage renal disease and kidney transplantation.
Transpl Int. 2014 Sep;27(9):877-91. doi: 10.1111/tri.12360. Epub 2014 Jun 19.
3
Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation.
Clin Transplant. 2011 Sep-Oct;25(5):794-9. doi: 10.1111/j.1399-0012.2010.01367.x. Epub 2010 Dec 16.
4
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
J Hepatol. 2017 Apr;66(4):718-723. doi: 10.1016/j.jhep.2016.12.020. Epub 2016 Dec 28.
5
Diabetes and Cardiovascular Risk in Renal Transplant Patients.
Int J Mol Sci. 2021 Mar 26;22(7):3422. doi: 10.3390/ijms22073422.
7
New Antivirals for Hepatitis C Infection Among Infected Kidney Transplant Recipients: A Case Report.
Transplant Proc. 2015 Nov;47(9):2672-4. doi: 10.1016/j.transproceed.2015.09.047.
8
Cardiovascular morbidity and mortality after kidney transplantation.
Transpl Int. 2015 Jan;28(1):10-21. doi: 10.1111/tri.12413. Epub 2014 Aug 20.
9
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
PLoS One. 2016 Jul 14;11(7):e0158431. doi: 10.1371/journal.pone.0158431. eCollection 2016.

引用本文的文献

1
Management of stage 1 renal cell cancer in patients immunosuppressed for organ transplantation or autoimmune disease.
Front Urol. 2023 Dec 8;3:1324696. doi: 10.3389/fruro.2023.1324696. eCollection 2023.
3
Acute Respiratory Distress Syndrome in Young Postrenal Transplant Patients Receiving Basiliximab.
Case Rep Crit Care. 2025 Feb 17;2025:1272468. doi: 10.1155/crcc/1272468. eCollection 2025.
5
Effect of CYP3A5*3, ABCC2 C-24T, and ABCC2 C3972T Genetic Polymorphisms on Direct Cost of Kidney Transplant Recipients.
Cureus. 2024 Sep 11;16(9):e69221. doi: 10.7759/cureus.69221. eCollection 2024 Sep.
6
Kynurenine Pathway after Kidney Transplantation: Friend or Foe?
Int J Mol Sci. 2024 Sep 14;25(18):9940. doi: 10.3390/ijms25189940.
7
Utility of Routine Post Kidney Transplant Anti-HLA Antibody Screening.
Kidney Int Rep. 2024 Feb 18;9(5):1343-1353. doi: 10.1016/j.ekir.2024.02.1394. eCollection 2024 May.
8
Exploration of wound-related complications post-kidney transplantation.
Int Wound J. 2024 Apr;21(4):e14578. doi: 10.1111/iwj.14578. Epub 2023 Dec 19.
9
Proteomic analysis of urinary extracellular vesicles of kidney transplant recipients with BKV viruria and viremia: A pilot study.
Front Med (Lausanne). 2022 Nov 17;9:1028085. doi: 10.3389/fmed.2022.1028085. eCollection 2022.

本文引用的文献

1
HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation.
J Clin Transl Hepatol. 2018 Sep 28;6(3):296-305. doi: 10.14218/JCTH.2018.00016. Epub 2018 Jul 6.
3
Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.
Ann Intern Med. 2018 Sep 4;169(5):273-281. doi: 10.7326/M18-0749. Epub 2018 Aug 7.
4
Influence of pretransplant midodrine use on outcomes after kidney transplantation.
Clin Transplant. 2018 Sep;32(9):e13366. doi: 10.1111/ctr.13366. Epub 2018 Aug 20.
7
Cardiovascular Disease After Kidney Transplant.
Semin Nephrol. 2018 May;38(3):291-297. doi: 10.1016/j.semnephrol.2018.02.008.
8
Timing of hepatitis C virus infection treatment in kidney transplant candidates.
Hemodial Int. 2018 Apr;22 Suppl 1:S61-S70. doi: 10.1111/hdi.12643.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验